Physician profile
Melissa Werner
NPI 1952060691
$5,794.45
in general payments reported to CMS, 2019-2025
18 companies · $2,983 in 2025
The $2,983 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,412 · 2024: $1,399 · 2025: $2,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,382.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ancora Heart, INC. | $1,412.39 | 2022 | |
| Abbvie INC. | $678.19 | 2024-2025 | |
| Axsome Therapeutics, INC. | $566.29 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $461.70 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $419.82 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $411.72 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.52 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $260.03 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $255.52 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $224.07 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $181.70 | 2024-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $167.81 | 2024-2025 | Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $148.40 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $80.89 | 2024-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $70.84 | 2024-2025 | Qelbree |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $57.94 | 2024-2025 | Loreev Xr |
| Tris Pharma INC | $43.14 | 2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $15.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.